PureTech sells minority shares in Karuna

Writer,

Clinical stage biotech company, PureTech Health, has announced it has sold 2.1 million shares of its affiliate, Karuna Therapeutics.

The cash sale has generated approximately $200 million which PureTech Health intends to use to fund its operations and growth for the foreseeable future and to further expand and advance its clinical stage, wholly owned pipeline.

Following the Transaction, PureTech continues to hold 5,295,397 shares of Karuna common stock, which is equal to 20.4% of Karuna's outstanding shares, and has a right to royalty payments on net sales of any commercialised product covered by a license granted by PureTech to Karuna.

The Transaction constitutes a class 2 transaction for the purposes of the UK Financial Conduct Authority's Listing Rules.


Related content

PureTech Health boosts wholly owned pipeline in 2019; says Covid-19 may eventually impact timelines

Clinical stage biotherapeutics company PureTech Health has reported a strong capital base with $321.5m in pro-forma cash in its annual results to 31 December 2019...

Thu, 09/04/2020 - 09:37


PureTech Health doses first patient in lymphoedema treatment study

Serious disease focused PureTech Health said the first participant had been dosed in a clinical study of a treatment for lymphoedema and other fibrotic conditions....

Tue, 03/03/2020 - 07:45


PureTech Health welcomes publication of ADHD treatment trial results

PureTech Health welcomed news that affiliate company Akili had published positive trial results for a treatment for attention-deficit/hyperactivity disorder in The Lancet Digital Health journal....

Tue, 25/02/2020 - 09:33


Broker Forecast - Liberum Capital issues a broker note on PureTech Health Plc

Liberum Capital today reaffirms its buy investment rating on PureTech Health Plc (LON:PRTC) and raised its price target to 450p (from 420p).

Broker Forecasts data...

Fri, 24/01/2020 - 10:20


Broker Forecast - Liberum Capital issues a broker note on PureTech Health Plc

Liberum Capital today reaffirms its buy investment rating on PureTech Health Plc (LON:PRTC) and cut its price target to 420p (from 450p).

Broker Forecasts data...

Mon, 13/01/2020 - 11:20